MOA Video
Ready to see what’s possible with VANRAFIA?
Curious about the VANRAFIA safety profile?
Interested in learning more?
Join an expert-led virtual discussion about VANRAFIA for the reduction of proteinuria in adults with primary IgAN at risk of rapid disease progression.
WARNING: EMBRYO-FETAL TOXICITY
VANRAFIA is contraindicated for use in pregnant patients; it may cause major birth defects, based on animal data. Exclude pregnancy prior to initiation of treatment with VANRAFIA. Advise use of effective contraception before the initiation of treatment, during treatment, and for 2 weeks after discontinuation of treatment with VANRAFIA. Stop VANRAFIA as soon as possible if the patient becomes pregnant...
VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
Definitions
ET-1, endothelin-1; ETA, endothelin A; ETB, endothelin B; MOA, mechanism of action.
Reference
1. Vanrafia. Prescribing information. Novartis Pharmaceuticals Corp.
